{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:13:18Z","timestamp":1754557998503},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"12","funder":[{"name":"National Research Council"},{"name":"National Agency for Scientific and Technological Promotion"},{"name":"Foundation Alberto J. Roemmers"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,25]]},"DOI":"10.1515\/cclm-2020-1482","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:08:34Z","timestamp":1624493314000},"page":"e449-e453","source":"Crossref","is-referenced-by-count":2,"title":["Development of an inverse-PCR approach for characterization of the major <i>BCR-ABL1<\/i> breakpoint sequences on genomic DNA: proof of concept"],"prefix":"10.1515","volume":"59","author":[{"given":"Leandro G.","family":"Guti\u00e9rrez","sequence":"first","affiliation":[{"name":"Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel M.","family":"Abelleyro","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Sol","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas-Fundaci\u00f3n C\u00e1ncer (CIO-FUCA) , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Sol","family":"Anchordoqui","sequence":"additional","affiliation":[{"name":"Argenomics , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefina","family":"Freitas","sequence":"additional","affiliation":[{"name":"Hospital Nacional Profesor Alejandro Posadas , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas-Fundaci\u00f3n C\u00e1ncer (CIO-FUCA) , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos D.","family":"De Brasi","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina"},{"name":"Instituto de Investigaciones Hematol\u00f3gicas (IIHEMA), Academia Nacional de Medicina , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene B.","family":"Larripa","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"2023033112143562569_j_cclm-2020-1482_ref_001","doi-asserted-by":"crossref","unstructured":"Fioretos, T, Bertil, F. Chapter 7: Chronic myeloid leukemia, In: Heim S, Mitelman F, editors. Cancer cytogenetics, 3rd ed. Hoboken, New Jersey: Wiley Blackwell, A John Wiley & Sons, Inc., Publication; 2009: 179\u2013207 pp.","DOI":"10.1002\/9781118010136.ch7"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_002","doi-asserted-by":"crossref","unstructured":"Cross, NCP, White, HE, Colomer, D, Ehrencrona, H, Foroni, L, Gottardi, E, et al.. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015;29:999\u20131003. https:\/\/doi.org\/10.1038\/leu.2015.29.","DOI":"10.1038\/leu.2015.29"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_003","doi-asserted-by":"crossref","unstructured":"Falchi, L, Kantarjian, H, Wang, X, Verma, D, Quint\u00e1s-Cardama, A, O\u2019Brien, S, et al.. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013;88:1024\u20139. https:\/\/doi.org\/10.1002\/ajh.23560.","DOI":"10.1002\/ajh.23560"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_004","doi-asserted-by":"crossref","unstructured":"Ross, DM, Branford, S, Seymour, JF, Schwarer, AP, Arthur, C, Bartley, PA, et al.. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719\u201324. https:\/\/doi.org\/10.1038\/leu.2010.185.","DOI":"10.1038\/leu.2010.185"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_005","doi-asserted-by":"crossref","unstructured":"Ross, DM, Hughes, TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol 2014;166:3\u201311. https:\/\/doi.org\/10.1111\/bjh.12892.","DOI":"10.1111\/bjh.12892"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_006","doi-asserted-by":"crossref","unstructured":"Pagani, IS, Dang, P, Kommers, IO, Goyne, JM, Nicola, M, Saunders, VA, et al.. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica 2018;103:2026\u201332. https:\/\/doi.org\/10.3324\/haematol.2018.189787.","DOI":"10.3324\/haematol.2018.189787"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_007","doi-asserted-by":"crossref","unstructured":"Score, J, Calasanz, MJ, Ottman, O. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia 2010;24:1742\u201350. https:\/\/doi.org\/10.1038\/leu.2010.174.","DOI":"10.1038\/leu.2010.174"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_008","doi-asserted-by":"crossref","unstructured":"Ross, DM, O\u2019Hely, M, Bartley, PA, Dang, P, Score, J, Goyne, JM, et al.. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia 2013;27:2105\u20137. https:\/\/doi.org\/10.1038\/leu.2013.116.","DOI":"10.1038\/leu.2013.116"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_009","doi-asserted-by":"crossref","unstructured":"Abelleyro, MM, Marchione, VD, Palmitelli, M, Radic, CP, Neme, D, Larripa, IB, et al.. Inverse PCR to perform long-distance haplotyping: main applications to improve preimplantation genetic diagnosis in hemophilia. Eur J Hum Genet 2019;27:603\u201311. https:\/\/doi.org\/10.1038\/s41431-018-0334-9.","DOI":"10.1038\/s41431-018-0334-9"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_010","doi-asserted-by":"crossref","unstructured":"Mattarucchi, E, Guerini, V, Rambaldi, A, Campiotti, L, Venco, A, Pasquali, F, et al.. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes Chromosomes Cancer 2008;47:625\u201332. https:\/\/doi.org\/10.1002\/gcc.20568.","DOI":"10.1002\/gcc.20568"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_011","doi-asserted-by":"crossref","unstructured":"Alikian, M, Ellery, P, Forbes, M, Gerrard, G, Kasperaviciute, D, Sosinsky, A, et al.. Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients. J Mol Diagn 2016;18:176\u201389. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.09.005.","DOI":"10.1016\/j.jmoldx.2015.09.005"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_012","doi-asserted-by":"crossref","unstructured":"Polakova, KM, Zizkova, H, Zuna, J, Motlova, E, Hovorkova, L, Gottschalk, A, et al.. Analysis of chronic myeloid leukemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia 2020;34:2113\u201324. https:\/\/doi.org\/10.1038\/s41375-020-0882-1.","DOI":"10.1038\/s41375-020-0882-1"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_013","doi-asserted-by":"crossref","unstructured":"Pagani, IP, Dang, P, Saunders, V, Grose, R, Shanmuganathan, N, Kok, C, et al.. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia 2020;34:1052\u201361. https:\/\/doi.org\/10.1038\/s41375-019-0647-x.","DOI":"10.1038\/s41375-019-0647-x"},{"key":"2023033112143562569_j_cclm-2020-1482_ref_014","doi-asserted-by":"crossref","unstructured":"Sobrinho-Simoes, M, Wilczek, V, Score, J, Cross, NCP, Apperley, JF, Melo, JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116:1329\u201335. https:\/\/doi.org\/10.1182\/blood-2009-11-255109.","DOI":"10.1182\/blood-2009-11-255109"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-1482\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-1482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T16:37:45Z","timestamp":1680280665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-1482\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6,23]]},"published-print":{"date-parts":[[2021,11,25]]}},"alternative-id":["10.1515\/cclm-2020-1482"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2020-1482","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}